跳至主要内容
临床试验/NCT00563277
NCT00563277Unknown不适用

Surgical Treatment of Concurrent Cataract and Primary Pterygium: A Randomized Control Trial

Hospital Authority, Hong Kong3 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2004年10月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
75
试验地点
3
主要终点
final refraction deviation from target

研究概览

简要总结

Pterygium is known to induce with-the-rule astigmatism. The corneal curvature along the long axis of the pterygium body is flattened. The excision of pterygium will result in steepening of the cornea and reduction of astigmatism. Therefore, the effect of pterygium excision on intraocular lens (IOL) power calculation has been examined in our previous study. The study confirmed that pterygium can cause alteration of IOL power.

The determination of IOL power for cataract surgery is usually calculated from IOL formula called SRK II formula. IOL power = A - (2.5 x AL)-(0.9 x K). Variable A denotes the A-constant of the intraocular lens which is dependent on the IOL material and refractive index. Other variables for input include axial length (AL) and keratometry (K). A larger K reading will result in a lower estimated IOL power and vice versa. Previous studies have documented simultaneous cataract and pterygium operation resulted in reasonable visual outcome without adjustment of IOL power.

With the presence of a pterygium, the cornea is flattened and lead to a reduction of K value and over-estimation of calculated IOL power. This randomized controlled trial is designed to compare the refractive outcomes of sequential and simultaneous pterygium and cataract operation.

Pterygium excision should be done with various adjuvant therapies to minimize recurrence. Our previous studies reliably demonstrated limbal conjunctival graft and mitomycin C were effective methods to achieve low pterygium recurrence. We use limbal conjunctival autograft as the adjuvant therapy in the current study because this method is safer to be performed either alone or in combination with phacoemulsification. We avoid using mitomycin C as the adjuvant therapy in order to minimize the possibility of intraocular toxicity due to seepage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • >18 years old
  • Primary pterygium > 2mm across corneal limbus [Measurement made from the imaginary line of surgical limbus to the most advance edge of the visible pterygium tissue] Concurrent visually significant cataract ( BCVA < 20/70 )
  • Informed consent for both pterygium and cataract surgery

排除标准

  • Temporal pterygium
  • Double headed pterygium
  • Previous ocular surgery in which conjunctival-limbal graft is not feasible
  • Pterygium covering visual axis that preclude keratometric assessment
  • History of scleritis or autoimmune diseases

结局指标

主要结局

final refraction deviation from target

时间窗: 1 and 3 months post cataract operation

次要结局

  • change of IOL power from pre-pterygium estimated power(1 and 3 months post pterygium excision)

研究者

发起方
Hospital Authority, Hong Kong
申办方类型
Other Gov

研究点 (3)

Loading locations...

相似试验

Surgical Treatment of Concurrent Cataract and... | 临床试验